New Novozymes exec to halt bleeding in struggling growth division
A priority for Novozymes Executive Vice President Tine Sejersgård Fanø is to halt the bleeding which has rendered the growth field of bioethanol a deep disappointment.
BY FINANS
2017 will be a fateful year for Novozymes, with critical focus on restoring investor confidence in the company.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novozymes welcomes new US biofuel requirements
For subscribers
Drax gets major biomass conversion approved
For subscribers
